Skip to main navigation
Horizon Therapeutics plc

U.S.

  • Global
    • Brazil
    • Canada
    • Germany
    • Japan
  • Investors
  • Media Hub
  • Stories
Horizon logo
search
  • Our Company
    • About Us
    • Leadership Team
    • Corporate Social Responsibility
    • Partnering
    • Grant Programs
    • Contact Us
  • Our Science
    • Research and Development
    • Pipeline
    • Science Forward
    • Clinical Trials
  • Our Medicines
    • Our Portfolio
    • Medical Resources
  • Our Patients
    • Our Commitment
      • Overview
      • Responsible Pricing
    • Advocacy
      • Overview
      • Resources
    • Disease Information
    • Patient Stories
    • Patient Support
    • Expanded Access
  • Careers
    • Why Horizon
    • Who We Are
    • Benefits
    • Job Opportunities
  • Investors
    • At a Glance
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Whistleblower Hotline
      • Leadership
      • Committee Composition
      • Contact Board
    • Financials & Filings
      • Financial Information
      • SEC Filings
      • GAAP to Non-GAAP Reconciliations
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Annual Reports / Proxy Statements
    • Investors FAQs
    • IR Contact Us
    • IR Email Alerts
  • Media Center
Follow Us

Press Releases

Press Releases

    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 25
    • 50
    Date Title View
    01/11/08
    Summary ToggleHorizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
    Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501 19.5 KB

    Pagination

    • First page First
    • Previous page Previous
    • …
    • Page 73
    • Page 74
    • Page 75
    • Current page 76
    Displaying 751 - 751 of 751 results

    Investor Relations

    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Whistleblower Hotline
      • Leadership Team
      • Committee Composition
      • Contact the Board
    • Financial & Filings
      • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Annual Reports / Proxy Statements
    • Investor FAQs
    • Contact Us
    • Email Alerts
    • Offer for Horizon Therapeutics plc
    Investor Contacts Tina Ventura
    Senior Vice President,
    Chief Investor Relations Officer
    Investor-relations@horizontherapeutics.com

    Ruth Venning
    Executive Director,
    Investor Relations and ESG
    Investor-relations@horizontherapeutics.com

    Erin Linnihan
    Executive Director,
    Investor Relations 
    Investor-relations@horizontherapeutics.com
    U.S. Media Contact Geoff Curtis
    Executive Vice President,
    Corporate Affairs & Chief
    Communications Officer
    media@horizontherapeutics.com
    +1 888 506-2562
    Ireland Media Contact Ray Gordon
    Gordon MRM
    ray@gordonmrm.ie
    +353 (87) 2417373
    Shareholder Tools

    Shareholder Tools

    • Email Alerts Subscription
    • RSS News Feeds
    • Snapshot
    • Print
    • Our Company
    • Our Science
    • Our Medicines
    • Our Patients
    • Careers
    • Investors
    • Follow Us
    © 2023 Horizon Therapeutics plc
    • Global Privacy Policy
    • Legal Notice
    • Cookie Policy
    • Contact Us

    The information regarding our medicines and the patients they treat on this site is intended only for residents of the U.S.

    You are leaving horizontherapeutics.com

    You are leaving horizontherapeutics.com. You will be redirected to a website operated by an independent third party. This link is provided solely for your convenience.

    Continue